Vaccine Investment Gets A Shot In The Arm
This article was originally published in Start Up
Executive Summary
The vaccine industry has had its ups and downs the last two decades, as public opinion and investor perception has influenced both the use and production of these preventative medicines. It’s traditionally been a difficult space for smaller companies due to the financial hurdles, but a handful of start-ups, including TremRx, Selecta Biosciences Inc., Genocea Biosciences Inc. and Imaxio SA, all profiled in this issue, are banking on progress in delivery and development technology to help them raise financing for their vaccines programs.